Charles Schwab Investment Management Inc. Increases Stock Position in UroGen Pharma Ltd. (NASDAQ:URGN)

Charles Schwab Investment Management Inc. raised its position in UroGen Pharma Ltd. (NASDAQ:URGN) by 9.1% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 90,493 shares of the company’s stock after buying an additional 7,576 shares during the period. Charles Schwab Investment Management Inc. owned about 0.39% of UroGen Pharma worth $1,149,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in URGN. Intech Investment Management LLC purchased a new position in shares of UroGen Pharma in the 3rd quarter valued at about $155,000. GSA Capital Partners LLP purchased a new position in UroGen Pharma during the third quarter worth approximately $249,000. Rice Hall James & Associates LLC grew its holdings in UroGen Pharma by 273.6% in the third quarter. Rice Hall James & Associates LLC now owns 271,897 shares of the company’s stock valued at $3,453,000 after purchasing an additional 199,110 shares during the period. China Universal Asset Management Co. Ltd. increased its position in shares of UroGen Pharma by 90.9% in the third quarter. China Universal Asset Management Co. Ltd. now owns 8,100 shares of the company’s stock valued at $103,000 after buying an additional 3,856 shares in the last quarter. Finally, Wesbanco Bank Inc. acquired a new position in shares of UroGen Pharma during the 3rd quarter worth approximately $945,000. Hedge funds and other institutional investors own 91.29% of the company’s stock.

UroGen Pharma Stock Performance

URGN opened at $11.33 on Wednesday. UroGen Pharma Ltd. has a twelve month low of $10.60 and a twelve month high of $20.70. The firm has a market capitalization of $265.73 million, a PE ratio of -3.60 and a beta of 1.06. The company has a current ratio of 9.00, a quick ratio of 8.77 and a debt-to-equity ratio of 4.77. The firm’s 50-day moving average price is $12.13 and its 200 day moving average price is $13.88.

UroGen Pharma (NASDAQ:URGN) last issued its earnings results on Wednesday, November 6th. The company reported ($0.55) earnings per share for the quarter, topping the consensus estimate of ($0.84) by $0.29. The company had revenue of $25.20 million for the quarter, compared to analyst estimates of $24.22 million. During the same quarter in the prior year, the firm earned ($0.68) earnings per share. As a group, sell-side analysts expect that UroGen Pharma Ltd. will post -3.1 EPS for the current fiscal year.

Wall Street Analyst Weigh In

URGN has been the topic of a number of research analyst reports. HC Wainwright reissued a “buy” rating and issued a $60.00 price target on shares of UroGen Pharma in a research note on Tuesday, October 15th. EF Hutton Acquisition Co. I upgraded shares of UroGen Pharma to a “strong-buy” rating in a research report on Monday, October 14th. D. Boral Capital restated a “buy” rating and set a $25.00 price target on shares of UroGen Pharma in a research report on Friday, December 6th. Oppenheimer reiterated an “outperform” rating and issued a $40.00 price objective on shares of UroGen Pharma in a report on Wednesday, October 16th. Finally, Guggenheim assumed coverage on UroGen Pharma in a research note on Thursday, August 22nd. They set a “buy” rating and a $40.00 price objective for the company. Five equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $43.70.

UroGen Pharma Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.